{"id":755261,"date":"2023-05-04T17:43:34","date_gmt":"2023-05-04T21:43:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ventyx-biosciences-to-report-first-quarter-2023-financial-results-on-may-11-2023\/"},"modified":"2023-05-04T17:43:34","modified_gmt":"2023-05-04T21:43:34","slug":"ventyx-biosciences-to-report-first-quarter-2023-financial-results-on-may-11-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ventyx-biosciences-to-report-first-quarter-2023-financial-results-on-may-11-2023\/","title":{"rendered":"Ventyx Biosciences to Report First Quarter 2023 Financial Results on May 11, 2023"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">ENCINITAS, Calif., May  04, 2023  (GLOBE NEWSWIRE) &#8212; Ventyx Biosciences, Inc. (Nasdaq: VTYX), (\u201cVentyx\u201d), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that it will report financial results for the first quarter ended March 31, 2023 after market close on May 11, 2023. Company management will host a conference call and webcast beginning at 4:30 p.m. ET \/ 1:30 p.m. PT that day to discuss the financial results and highlight recent pipeline and business progress.<\/p>\n<p align=\"justify\">To participate in the conference call, please dial (800) 225-9448 (U.S.) or (203) 518-9708 (international) and reference passcode VTYXQ123. A live audio webcast will be available in the Investors section of the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UPAj8CpHwSW5zNMMBJK77TSE5EtS_5MgIGGBd4rvFi7EGjbvkeM5IXji4DdkV4RHwx3vFM6uTYwK2oyGQYo7CQ==\" rel=\"nofollow noopener\" target=\"_blank\">www.ventyxbio.com<\/a>. A recording of the webcast will be available for thirty days following the call.<\/p>\n<p align=\"justify\">\n        <strong>About Ventyx Biosciences<\/strong>\n      <\/p>\n<p align=\"justify\">Ventyx is a clinical-stage biopharmaceutical company focused on developing innovative oral medicines for patients living with autoimmune and inflammatory disorders. We believe our ability to efficiently discover and develop differentiated drug candidates will allow us to address important unmet medical need with novel oral therapies that can shift immunology markets from injectable to oral drugs. Our current pipeline includes three internally discovered clinical programs targeting TYK2, S1P1R and NLRP3, positioning us to become a leader in the development of oral immunology therapies. Ventyx is headquartered in Encinitas, California. For more information about Ventyx, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UPAj8CpHwSW5zNMMBJK77WkXoT33jzUH19nFw7gyXJp3P2dYbMeEovTb5d41lEFvwTunlfo6sUh7qWXOk6fujg==\" rel=\"nofollow noopener\" target=\"_blank\">www.ventyxbio.com<\/a>.<\/p>\n<p>\n        <strong>Investor Relations Contact<\/strong><br \/>\n        <br \/>Patti Bank<br \/>Managing Director<br \/>ICR Westwicke<br \/>(415) 513-1284<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pXxShTbr9fmYOhdOEJ4__Od5lhFu-ofJf_-RTi2fkRiRgJh905DvGeZR1igf1AqcWcI8hZGvBMQUoyEA7EB85w==\" rel=\"nofollow noopener\" target=\"_blank\">IR@ventyxbio.com<\/a>\u00a0<\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMjE3NCM1NTc1NTczIzIyMTA3MjU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NmM3M2E0NGItNGQ4YS00NjBmLThlMTctMzY1NGIxMmRhZDIzLTEyMjIyNzg=\/tiny\/Ventyx-Biosciences-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ENCINITAS, Calif., May 04, 2023 (GLOBE NEWSWIRE) &#8212; Ventyx Biosciences, Inc. (Nasdaq: VTYX), (\u201cVentyx\u201d), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that it will report financial results for the first quarter ended March 31, 2023 after market close on May 11, 2023. Company management will host a conference call and webcast beginning at 4:30 p.m. ET \/ 1:30 p.m. PT that day to discuss the financial results and highlight recent pipeline and business progress. To participate in the conference call, please dial (800) 225-9448 (U.S.) or (203) 518-9708 (international) and reference passcode VTYXQ123. A live audio webcast will be available in the Investors &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ventyx-biosciences-to-report-first-quarter-2023-financial-results-on-may-11-2023\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ventyx Biosciences to Report First Quarter 2023 Financial Results on May 11, 2023&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-755261","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ventyx Biosciences to Report First Quarter 2023 Financial Results on May 11, 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ventyx-biosciences-to-report-first-quarter-2023-financial-results-on-may-11-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ventyx Biosciences to Report First Quarter 2023 Financial Results on May 11, 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ENCINITAS, Calif., May 04, 2023 (GLOBE NEWSWIRE) &#8212; Ventyx Biosciences, Inc. (Nasdaq: VTYX), (\u201cVentyx\u201d), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that it will report financial results for the first quarter ended March 31, 2023 after market close on May 11, 2023. Company management will host a conference call and webcast beginning at 4:30 p.m. ET \/ 1:30 p.m. PT that day to discuss the financial results and highlight recent pipeline and business progress. To participate in the conference call, please dial (800) 225-9448 (U.S.) or (203) 518-9708 (international) and reference passcode VTYXQ123. A live audio webcast will be available in the Investors &hellip; Continue reading &quot;Ventyx Biosciences to Report First Quarter 2023 Financial Results on May 11, 2023&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ventyx-biosciences-to-report-first-quarter-2023-financial-results-on-may-11-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-04T21:43:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMjE3NCM1NTc1NTczIzIyMTA3MjU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ventyx-biosciences-to-report-first-quarter-2023-financial-results-on-may-11-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ventyx-biosciences-to-report-first-quarter-2023-financial-results-on-may-11-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ventyx Biosciences to Report First Quarter 2023 Financial Results on May 11, 2023\",\"datePublished\":\"2023-05-04T21:43:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ventyx-biosciences-to-report-first-quarter-2023-financial-results-on-may-11-2023\\\/\"},\"wordCount\":260,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ventyx-biosciences-to-report-first-quarter-2023-financial-results-on-may-11-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMjE3NCM1NTc1NTczIzIyMTA3MjU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ventyx-biosciences-to-report-first-quarter-2023-financial-results-on-may-11-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ventyx-biosciences-to-report-first-quarter-2023-financial-results-on-may-11-2023\\\/\",\"name\":\"Ventyx Biosciences to Report First Quarter 2023 Financial Results on May 11, 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ventyx-biosciences-to-report-first-quarter-2023-financial-results-on-may-11-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ventyx-biosciences-to-report-first-quarter-2023-financial-results-on-may-11-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMjE3NCM1NTc1NTczIzIyMTA3MjU=\",\"datePublished\":\"2023-05-04T21:43:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ventyx-biosciences-to-report-first-quarter-2023-financial-results-on-may-11-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ventyx-biosciences-to-report-first-quarter-2023-financial-results-on-may-11-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ventyx-biosciences-to-report-first-quarter-2023-financial-results-on-may-11-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMjE3NCM1NTc1NTczIzIyMTA3MjU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMjE3NCM1NTc1NTczIzIyMTA3MjU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ventyx-biosciences-to-report-first-quarter-2023-financial-results-on-may-11-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ventyx Biosciences to Report First Quarter 2023 Financial Results on May 11, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ventyx Biosciences to Report First Quarter 2023 Financial Results on May 11, 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ventyx-biosciences-to-report-first-quarter-2023-financial-results-on-may-11-2023\/","og_locale":"en_US","og_type":"article","og_title":"Ventyx Biosciences to Report First Quarter 2023 Financial Results on May 11, 2023 - Market Newsdesk","og_description":"ENCINITAS, Calif., May 04, 2023 (GLOBE NEWSWIRE) &#8212; Ventyx Biosciences, Inc. (Nasdaq: VTYX), (\u201cVentyx\u201d), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that it will report financial results for the first quarter ended March 31, 2023 after market close on May 11, 2023. Company management will host a conference call and webcast beginning at 4:30 p.m. ET \/ 1:30 p.m. PT that day to discuss the financial results and highlight recent pipeline and business progress. To participate in the conference call, please dial (800) 225-9448 (U.S.) or (203) 518-9708 (international) and reference passcode VTYXQ123. A live audio webcast will be available in the Investors &hellip; Continue reading \"Ventyx Biosciences to Report First Quarter 2023 Financial Results on May 11, 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ventyx-biosciences-to-report-first-quarter-2023-financial-results-on-may-11-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-04T21:43:34+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMjE3NCM1NTc1NTczIzIyMTA3MjU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ventyx-biosciences-to-report-first-quarter-2023-financial-results-on-may-11-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ventyx-biosciences-to-report-first-quarter-2023-financial-results-on-may-11-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ventyx Biosciences to Report First Quarter 2023 Financial Results on May 11, 2023","datePublished":"2023-05-04T21:43:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ventyx-biosciences-to-report-first-quarter-2023-financial-results-on-may-11-2023\/"},"wordCount":260,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ventyx-biosciences-to-report-first-quarter-2023-financial-results-on-may-11-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMjE3NCM1NTc1NTczIzIyMTA3MjU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ventyx-biosciences-to-report-first-quarter-2023-financial-results-on-may-11-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ventyx-biosciences-to-report-first-quarter-2023-financial-results-on-may-11-2023\/","name":"Ventyx Biosciences to Report First Quarter 2023 Financial Results on May 11, 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ventyx-biosciences-to-report-first-quarter-2023-financial-results-on-may-11-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ventyx-biosciences-to-report-first-quarter-2023-financial-results-on-may-11-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMjE3NCM1NTc1NTczIzIyMTA3MjU=","datePublished":"2023-05-04T21:43:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ventyx-biosciences-to-report-first-quarter-2023-financial-results-on-may-11-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ventyx-biosciences-to-report-first-quarter-2023-financial-results-on-may-11-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ventyx-biosciences-to-report-first-quarter-2023-financial-results-on-may-11-2023\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMjE3NCM1NTc1NTczIzIyMTA3MjU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMjE3NCM1NTc1NTczIzIyMTA3MjU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ventyx-biosciences-to-report-first-quarter-2023-financial-results-on-may-11-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ventyx Biosciences to Report First Quarter 2023 Financial Results on May 11, 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/755261","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=755261"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/755261\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=755261"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=755261"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=755261"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}